Clinical

The patient continued to test positive for COVID-19, but intravenous immunoglobulin eventually led to his recovery.

The FDA added another indication for semaglutide (Wegovy), expanding its use to reduce the risk of cardiovascular death, heart attack, or stroke in adults who have cardiovascular disease (CVD) and overweight or obesity.

Patients with diabetes whose providers received advice from remote, virtual interdisciplinary rounds had a greater 1-year reduction in hemoglobin A1c than comparable patients.

Preventive measures can reduce the risk to newborns, but careful monitoring is necessary, the authors said.

Self-management (SM) among older patients with chronic obstructive pulmonary disease (COPD) is moderately low, and frailty and depression may partially mediate the relationship between social support and SM in these patients.

A review of research confirms that adolescents and young adults (AYA) with myeloproliferative neoplasms (MPN) face psychological burdens but the exact burden is poorly understood.

The FDA has pushed back its approval deadline for donanemab, Eli Lilly’s experimental Alzheimer’s treatment; Cigna recently announced the launch of a program on aimed at capping annual weight-loss drug cost increases for health insurance providers and employers at 15%; a new monoclonal antibody product to protect against respiratory syncytial virus (RSV) was 90% effective at preventing children from being hospitalized.

This article analyzes the use of MRI in a national sample of patients with wrist pain before and after consensus guideline publication.

Camilla Levister, MS, ANP-C, CDCES, a nurse practitioner at the Icahn School of Medicine at Mount Sinai Hospital in New York, discusses how closed-loop artificial pancreas systems can help reduce the burden of type 1 diabetes (T1D) management during pregnancy.

The group showed that their 14-day model using an easily measurable calculation was able to predict long-term mortality as well as the traditional model using responses from 2 weeks later.

The FDA approval of nivolumab plus cisplatin and gemcitabine marks the first concurrent immunotherapy-chemotherapy combination for the population.

Differences in bone density and FRAX fracture risk scores among Black and Asian women yield greater discordance in fracture risk estimation compared with White women.

A prediction model using age, body mass index, lifestyle, waist circumference, and family history had high accuracy when used to predict colorectal cancer (CRC) in China.

A recent study found that tumor-stroma proportion was a reliable marker of chemoresistance, progression-free survival, and overall survival in high-grade serous ovarian cancer.

Developing accurate predictive models for patients with pediatric acute myeloid leukemia (AML) can close the preclinical gap in treatment for the rare disease.

Despite its impact on patient quality of life, hidradenitis suppurativa (HS) remains underdiagnosed and undertreated; authors outline what's being discovered within the treatment landscape.

In patients with chronic obstructive pulmonary disease (COPD), the higher the oxidative balance score, the lower the frailty risk, especially in women.

A patient with chronic lymphocytic leukemia (CLL) who experience persistent exaggerated responses to insect bites was successfully treated with dupilumab.

The National Comprehensive Cancer Network (NCCN) recommends ropeginterferon alfa-2b as first-line cytoreductive therapy for polycythemia vera.

While the results of evolutionRMS, comparing evobrutinib with teriflunomide, were negative, that "doesn't mean that evobrutinib is not working," said Xavier Montalban, MD, PhD, director of the Multiple Sclerosis Center of Catalonia (Cemcat).

Outcomes for patients with diabetic macular edema did not have treatment with intravitreal dexamethasone implants affected by their glycosylated hemoglobin.

Robert Gabbay, MD, PhD, delineates key differences between type 1 and type 2 diabetes, including autoimmune antibodies, insulin resistance, and insulin deficiency.

Wyost and Jubbonti were approved as interchangeable biosimilars for Xgeva and Prolia; however, there is no launch date yet pending litigation with the maker of the reference products.

The fully humanized monoclonal antibody led to results among patients with generalized myasthenia gravis (MG) similar to that of efgartigimod, the authors said.

A medical expert discusses efficacy of approaches such as carboplatin doublets, checkpoint inhibitors, and PARP inhibitors for patients with platinum sensitive and platinum-resistant ovarian cancer.